Large Molecule Quantification

Address the quantification of peptide- and protein-based biotherapeutics and biomarkers.

Sign up to receive updates

Development of a SPE LC-MS/MS Method for the Bioanalytical Quantification of Salmon Calcitonin from Human Serum

This application note describes a simple sample preparation strategy using Oasis WCX μElution SPE combined with analytical flow LC and a tandem (triple) quadrupole MS for the high sensitivity quantification of salmon calcitonin from human serum.

Oasis Peptide Bioanalysis Reference Card

This reference card highlights bioanalytical sample preparation and method development for therapeutic and endogenous peptides.

High Resolution Mass Spectrometry for Quantitative and Qualitative (Quant/Qual) Bioanalysis of Antibody-based Therapeutics using Intact mAb and Subunit Detection

John T. Mehl, Ph.D Sr. Research Investigator, Bioanalytical Research Bristol-Myers Squibb

As antibody-based therapeutics become more common and more structurally complex, there is an increased need for more in depth understanding of the in vivo disposition of this class of drug modality. This presentation provides an overview of affinity sample preparation and highlight examples of how both Intact and subunit mAb bioanalysis provides insight into the in vivo disposition of antibody-based therapeutics.

Developing bioanalytical assays and workflows for peptide/protein biomarkers and biotherapeutics: Getting the right assay the first time

Matt Szapacs, Ph.D Group Leader Exploratory Biomarker Assay Group GlaxoSmithKline

In recent years the use of LC-MS technologies for the quantitation of peptide/protein biomarkers has increased dramatically. This presentation focuses on case studies highlighting the use of systematic method development strategies for both intact analysis and methods involving digestion. In addition, instrument selection (High resolution vs. QQQ) will be highlighted.

A Powerful Hybrid IA-LC-MS/MS Method for Routine Quantification of Insulin Analogues and their Biosimilars in Clinical Trial Samples

Michael Blackburn, M.Phil Bioanalytical Scientist, Method Development Specialist ARCINOVA

Mass spectrometry based assays are rapidly becoming the gold standard for the analysis of insulin biosimilars, and are increasingly requested by regulatory authorities during clinical trials for new diabetic therapies, due to their superior specificity. In this presentation, we show how the sensitivity of the Xevo TQ-XS combined with immunoaffinity extraction and UPLC enables bioanalysts to bring new compounds to market.

A Guide to Performing Method Development for Direct Injection Methods Using ionKey/MS in a Bioanalytical Laboratory: From Sample Preparation to LC-MS

This white paper describes a suggested approach to developing methods for use with the ionKey/MS System. The instrumentation may consist of the ACQUITY UPLC M-Class System, and any Xevo/SYNAPT Mass Spectrometer that can be fitted with an ionKey source.

Comparison between the Tandem Quadrupole and Quadrupole Time-Of-Flight Quantification of Exenatide in Rat Plasma

This poster was presented at the 2018 ASMS annual conference from June 3-7 in San Diego, CA.

LC-MS/MS Quantification of Intact Insulin-Like Growth Factor I (IGF-I) from Serum for Clinical Research

This poster was presented at the 2018 ASMS annual conference from June 3-7 in San Diego, CA.

Peptide Catabolite Identification Using HDMSE data and Mass-MetaSite Processing

This poster was presented at the 2018 ASMS annual conference from June 3-7 in San Diego, CA.

Evaluation of Intelligent Software Tools for the Metabolite Profiling and Identification of Peptide-Based Large Molecules

This poster was presented at the 2018 ASMS annual conference from June 3-7 in San Diego, CA.